Using the ratio of the amount of beta-amyloid 1-42 to the total tau index makes it possible to identify patients with neurodegenerative disorders with high accuracy as well as to distinguish patients with Alzheimer’s disease from patients with other forms of dementia with moderate accuracy [10]. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.